Because RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), increase the levels of ACE2, the protein that facilitates the entry of SARS-CoV-2 into cells, there are concerns that these drugs could increase the risks of severe COVID-19 and mortality (4). This evidence concerns the gene ACE2 and COVID-19.